Case No. 2015-826
SUMMARY
UCLA researchers in the Department of Chemistry and Biochemistry have developed a novel method for high protein expression levels, in situ, involving RNA-based therapeutics.
BACKGROUND
The RNA therapeutics industry is growing at a CAGR of 12% and is expected to reach $1.2 billion by 2020. These are a novel class of therapeutics, currently in clinical trials for cancer, immunotherapy and vaccination. An RNA therapeutic is essentially an mRNA that codes for any gene of interest, such as an antibody or an immune modulatory protein. Upon delivery of the mRNA, the cellular machinery initiates production and thus provides an in vivo synthesis of the therapeutic. However, there are a number of challenges confronting clinical applications of this technology. The instability of RNA and reduced longevity of its effects requires that patients receive regular doses for long-term effects.
INNOVATION
UCLA researchers have developed a novel approach for sustained RNA expression in vivo. Using their own technology of artificial and non-infectious virus-like particles, they have developed a method to deliver any gene of interest. Their novel approach can yield 100-1000 times higher levels of production of the gene of interest than delivery of mRNA. It can be used for therapeutic delivery, imaging purposes, as a vaccine platform, as well as for research purposes. The key idea involves the protection of two RNA molecules in identical but separate virus-like particles – one containing the gene of interest, and the other containing the gene for an RNA replicase that will strongly amplify the gene of interest.
APPLICATIONS
Sustained expression of large proteins such as antibodies for passive immunization
Sustained expression of any therapeutics
Research tool for expression of any desired gene in vivo
Immunomodulation for cancer therapy
ADVANTAGES
Simple approach compatible with any gene of interest involving in vitro syntheses from purified components
Can be used for expressing large genes and proteins such as antibodies